Acomplia Labelling To Change In EU Regarding Diabetes

Sanofi Aventis are very keen to get Acomplia known as a drug to treat diabetes

Some good news for the drug company Sanofi Aventis that makes the weight loss medication Acomplia is that the EMEA which regulates drug sales and marketing for the European Union has allowed the company to mention the fact that Acomplia can help patients who have blood sugar problems in the form of diabetes.

The EMEA specifically said that Sanofi Aventis can now let patients know that Acomplia could help in diabetic blood sugar control but they also said that this does not mean that it is now approved and can be prescribed as a drug for diabetes.

This means that from now on any Acomplia sold in the European Union will have a change on the labelling to inform patients and doctors of the positive effect that the drug can have on diabetes. At present the labeling of the Acomplia drug only mentioned that it is to be used with diet and exercise to help obese people lose weight or to help overweight people who have diabetes or other illnesses related to their weight.

Sanofi Aventis are very keen to get Acomplia known as a drug to treat diabetes and not just as a weight loss medication. This is extremely important to them because if the drug is prescribed as a diabetes medication it will be covered by most health insurance policies and this will mean that sales will rise. At present health insurance companies are not keen to reimburse patients for weight loss medication except in extreme circumstances.

Sanofi Aventis are still busy testing the Acomplia weight loss medication as the Food & Drug Administration of America requires more information before they will give full permission for the drug to be sold in America. Acomplia is sold in many countries around the world and has produced good results with most patients use it.